LEPR: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of LEPR. The page also collects GeneMedi's different modalities and formats products for LEPR in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the LEPR target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Secreted Protein/Potential Cytokines.
The protein encoded by this gene belongs to the gp130 family of cytokine receptors that are known to stimulate gene transcription via activation of cytosolic STAT proteins. This protein is a receptor for leptin (an adipocyte-specific hormone that regulates body weight), and is involved in the regulation of fat metabolism, as well as in a novel hematopoietic pathway that is required for normal lymphopoiesis. Mutations in this gene have been associated with obesity and pituitary dysfunction. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. It is noteworthy that this gene and LEPROT gene (GeneID:54741) share the same promoter and the first 2 exons, however, encode distinct proteins (PMID:9207021).[provided by RefSeq, Nov 2010]
Target ID | GM-T17163 |
Target Name | LEPR |
Gene ID | 3953 |
Gene Official Name | LEPR |
Gene Alias | CD295, LEP-RD, OB-R, OBR, LEPR |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Therapeutics Target, INN Index |
Pre-made LEPR-specific INN-index biosimilar (antibody&conjugates)-Mibavademab
Anti-LEPR therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Order |
GMP-Bios-ab-343 | Pre-Made Mibavademab biosimilar, Whole mAb, Anti-LEPR Antibody: Anti-CD295/OB-R/OBR therapeutic antibody | Mibavademab | LEPR | Whole mAb | ![]() |
Pre-made anti-LEPR inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-LEPR benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-LEPR mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cat No. | Antibody Name | Format | Classified by tag | Order |
GM-Tg-hg-T17163-Ab | Anti-LEPR monoclonal antibody | mab | Biofunctional antibody, Therapeutics Target antibody | ![]() |